BioSpace News Archive

Drug Development

Mirati’s Sitravatinib Fails in Phase III Lung Cancer Trial, Nixes Development

The investigational kinase inhibitor failed to improve overall survival in the SAPPHIRE study of patients with non-squamous non-small cell lung cancer, causing Mirati to discontinue its development.

May 25, 2023
·
2 min read
·
Tristan Manalac
Drug Development

Opinion: What to Expect From an Experimental Anti-Abuse Opioid Drug

Although still in early-stage testing, Ensysce Biosciences’ formulation has demonstrated the potential to address addiction problems associated with oral oxycodone.

May 25, 2023
·
3 min read
·
Jia Jie Chen
Business

BenevolentAI Cuts Workforce, Pipeline in Strategic Realignment

The AI drug discovery company’s reorganization will include laying off around 180 employees and dropping its atopic dermatitis candidate BEN-2293 in an effort to save nearly $56 million.

May 25, 2023
·
2 min read
·
Tristan Manalac
FDA

Braeburn’s Long-Acting Brixadi Receives FDA Clearance to Treat Opioid Use Disorder

The FDA approved Braeburn Pharmaceuticals’ new buprenorphine treatment option with extended-release medication that could pave the way for greater patient compliance.

May 25, 2023
·
3 min read
·
Lisa Munger
Drug Development

Annexon Sets Sights on Phase III Geographic Atrophy Trial Despite Missing Mid-Stage Mark

The company’s candidate, ANX007, did not significantly slow lesion growth in a Phase II trial but was effective at preserving visual function in patients with a form of dry age-related macular degeneration.

May 25, 2023
·
2 min read
·
Tristan Manalac
Drug Development

Apellis Drops ALS Candidate After Disappointing Phase II Results

The Massachusetts-based biopharma became the second company this week to drop its amyotrophic lateral sclerosis hopeful after it failed to elicit significant improvement compared with placebo.

May 25, 2023
·
2 min read
·
Rosemary Scott
Avivagen Announces Significant Increase in Sales to an Existing Customer

Avivagen Inc. is pleased to announce that an existing customer has placed an order sized at 400% of its normal monthly order volume.

May 25, 2023
·
4 min read
Genetown

Dyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation for DYNE-101

Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that the European Medicines Agency (EMA) has granted orphan drug designation for DYNE-101.

May 25, 2023
·
6 min read
Business

Syneos Health Appoints Batisha Anson to Global Head, Patient Diversity and Health Equity

Syneos Health®, a leading fully integrated biopharmaceutical solutions organization, announced the appointment of Batisha Anson to the newly created role of Global Head of Patient Diversity and Health Equity.

May 25, 2023
·
3 min read
Olink to participate in June 2023 investor events

Olink Holding AB, announced that Company management will participate in the following investor events.

May 25, 2023
·
1 min read